Traders work on the floor of the New York Stock Exchange.
(This story is for CNBC Pro subscribers only).
Positive news around multiple vaccine candidates has helped boost the stock market in recent weeks, but the economic reopening does not appear to be fully priced in for some stocks, according to UBS.
Researchers at the firm looked for stocks that had been hit hard during the pandemic, and their stock price didn’t reflect the earnings potential in 2022 and possible margin improvement.
Originally published at CNBC